Sangamo Biosciences Inc (SGMO)

[Cincinnatus]

Question from the multiple-challenged investor??

Would anyone be willing to help out WE who are challenged by math (stat sig?), science, FDA study speak, and just plain old senility??

What sort of numbers/percentages on the primary and secondary endpoints would be considered

A) Super
B) Adequate
C) Borderline/ambiguous
D) Awful.

TIA